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Objectives. This study sought to verify the effectiveness of
pharmacologic stress echocardiography in risk stratification of
patients with single-vessel disease.
Background. Noninvasive prognostic assessment of single-
vessel disease is an unresolved issue to date.
Methods. The study evaluated prospectively collected data from
754 patients with angiographic single-vessel disease who under-
went either dipyridamole (n 5 576) or dobutamine (n 5 178)
stress echocardiography. Invasive treatment (coronary revascu-
larization within 3 months of stress testing) was performed in 260
patients and medical treatment in 494.
Results. Echocardiographic positivity was observed in 421
patients (56%). Patients treated invasively had a higher incidence
of stress test positivity (69% vs. 49%, p < 0.001) and left anterior
descending coronary artery involvement (60% vs. 46%, p < 0.001)
than patients maintained with medical therapy. During a mean
follow-up of 37 months, 54 hard cardiac events occurred (14
deaths, 40 nonfatal infarctions): 37 in medically and 17 in
invasively treated patients (7.5% vs. 6.5%, p 5 NS). On Cox
analysis, a positive result on stress testing was the only indepen-
dent prognostic predictor in medically treated patients (relative
risk 2.92, 95% confidence interval 1.29 to 6.59). The 4-year
infarction-free survival rate was higher for a negative than a
positive stress test result in medically (93.9% vs. 87.3%, p 5 0.009)
but not invasively treated patients (92.7% vs. 97.1%, p 5 0.545).
Moreover, a significantly higher 4-year infarction-free survival
rate was found in invasively versus medically treated patients with
a positive (p 5 0.012), but not in those with a negative, stress test
result (p 5 0.853).
Conclusions. Pharmacologic stress echocardiography is effec-
tive in risk stratification of single-vessel disease and can accu-
rately discriminate patients in whom coronary revascularization
can have the maximal beneficial effect. These findings have a
potential favorable impact on the cost-effectiveness of invasive
procedures.
(J Am Coll Cardiol 1998;32:69–74)
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The natural history of single-vessel disease is generally benign
(1–3). In the subset of patients with an angiographically proved
low risk profile, several techniques have been proposed for risk
stratification, including exercise stress testing (4,5) and stress
nuclear cardiac techniques (6–10). To verify the effectiveness
of pharmacologic stress echocardiography for identifying high
risk patients with single-vessel disease, data from 754 patients
prospectively enrolled in the Echo-Persantine International
Cooperative (EPIC) and Echo-Dobutamine International Co-
operative (EDIC) studies were analyzed.
Methods
Patients. From the EPIC–EDIC data bank, 754 prospec-
tively enrolled patients from eight centers (each contribut-
ing .50 patients) were selected. They met the following
inclusion criteria: 1) pharmacologic stress echocardiography
with either dipyridamole (n 5 576) or dobutamine (n 5
178); 2) technically acceptable echocardiographic study at
baseline; 3) coronary angiography performed systematically
after stress echocardiography (within 30 days) and showing
a single-vessel disease, defined as $75% visually assessed
diameter reduction in a major coronary artery vessel (left
anterior descending or large diagonal branch; left circumflex
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or large marginal branch; and right coronary artery); 4) no
significant left main disease (#50% stenosis); 5) no history
of previous coronary revascularization procedure (angio-
plasty or operation); 6) enrollment in a follow-up program.
No patient meeting the inclusion criteria was excluded from
the study for refusing follow-up.
Of 754 patients, 260 underwent invasive treatment consist-
ing of coronary revascularization with either angioplasty (n 5
224) or operation (n 5 36) within 3 months of stress echocar-
diography. The remaining 494 patients were maintained with
medical therapy, consisting of risk factor modification as well
as antiplatelet therapy, nitrates and beta-adrenergic and cal-
cium channel blocking agents individually or in combination at
a dosage adequate for relieving angina without inducing
intolerable side effects. The choice of invasive over medical
treatment was made by the physician on the basis of symptoms,
coronary anatomy, left ventricular function, stress echocardio-
graphic result and general condition of the individual patient.
The clinical and angiographic characteristics as well as baseline
and stress echocardiography results are shown in Table 1.
Stress protocols. Two-dimensional echocardiography and
12-lead electrocardiographic (ECG) monitoring were per-
formed in combination with either high dose dipyridamole (up
to 0.84 mg over 10 min) or high dose dobutamine (up to
40 mg/kg body weight per min, with coadministration of
atropine up to 1 mg), according to the well established
protocols (11,12). Starting in January 1992, the dipyridamole
protocol was modified to include coadministration of atropine
(up to 1 mg) (13). During the procedure, blood pressure and
the ECG were recorded each minute.
Echocardiographic analysis. Two-dimensional echocardio-
grams were obtained with commercially available imaging
systems. Echocardiographic images were recorded on VHS
videotape for subsequent playback and analysis. Regional wall
motion was assessed according to the recommendations of the
American Society of Echocardiography with a 16-segment
model (14). In all studies, segmental wall motion was semiquan-
titatively graded from 1 to 4 as follows: 1 5 normal (normal
motion at rest, with normal/increased wall motion [hyperkine-
sia] after dipyridamole or dobutamine); 2 5 hypokinetic
(marked reduction in endocardial motion and thickening); 3 5
akinetic (virtual absence of inward motion and thickening); 4 5
dyskinetic (paradoxic wall motion away from the center of the
left ventricle in systole). The wall motion score index was
derived by dividing the sum of individual segment scores by the
number of interpretable segments. The only criterion of test
positivity was defined as the occurrence of new or worsening
preexisting dyssynergy (i.e., normokinesia becoming hypokine-
sia, akinesia or dyskinesia, or hypokinesia becoming akinesia
or dyskinesia). However, rest akinesia becoming dyskinesia
was not considered a positive result because the change could
be due to passive stretching phenomena rather than “active”
ischemia. An ST segment shift $0.1 mV from baseline at 80 ms
after the J point in at least two contiguous leads was also noted.
Nonechocardiographic end points requiring test interruption
without echocardiographic positivity were the following: peak
dipyridamole or dobutamine plus atropine dose; achievement
of 85% of target heart rate (i.e., Predicted target heart rate 5
220 2 Age); achievement of conventional end points, such as
severe chest pain or significant ST segment changes, or both.
The test was also stopped, in the absence of diagnostic end
points, for one of the following reasons of submaximal test
results: 1) intolerable symptoms; and 2) limiting asymptomatic
side effects, including hypertension (systolic blood pressure
.220 mm Hg; diastolic blood pressure .120 mm Hg), hypo-
tension (relative or absolute: .30-mm Hg decrease in blood
pressure), supraventricular arrhythmias (supraventricular
tachycardia or atrial fibrillation), ventricular arrhythmias (ven-
tricular tachycardia; frequent, polymorphous premature ven-
tricular beats).
At each center, one observer (L.C., E.P., M.P., S.P., P.B.,
R.B., O.M., A.G.) who had passed the quality control proce-
dures detailed elsewhere (15) reviewed the study; his or her
reading was entered directly into the data bank. Investigators
were unaware of the clinical outcome of the individual patient
before they submitted their stress test interpretation.
Coronary angiography. Coronary angiography was per-
formed in multiple projections using the standard Judkins or
Sones technique. Significant coronary artery disease was defined
as $75% visually assessed reduction of the lumen diameter of
any of the three coronary arteries or their primary branches.
All angiograms were reviewed by two independent observers
who were unaware of the stress test results.
Follow-up data. Follow-up data were obtained from at
least one of four sources: 1) review of the patient’s hospital
record; 2) personal communication with the patient’s physician
and review of the patient’s chart; 3) telephone interview with
the patient conducted by trained personnel; or 4) patient visits
to a staff physician at regular intervals in the outpatient clinic.
By inclusion criteria, follow-up data were obtained for all
patients.
Events were defined as cardiac-related death and nonfatal
myocardial infarction. For patients who died in the hospital or
at home, the cause of the death was elucidated from the
medical record, the family and the local physician who signed
the death certificate. Cardiac-related death required documen-
tation of significant arrhythmias or cardiac arrest, or both, or
death attributable to congestive heart failure or myocardial
infarction in the absence of any other precipitating factors.
Death out of the hospital for which no autopsy was performed,
was classified as sudden unexpected death and was attributed to
a cardiac cause. Myocardial infarction was defined as a cardiac
event requiring admission to the hospital, with development of
new ECG changes and cardiac enzyme level increases.
Therefore, the outcome events were hard cardiac events
Abbreviations and Acronyms
ECG 5 electrocardiogram, electrocardiographic
EDIC 5 Echo-Dobutamine International Cooperative Study
EPIC 5 Echo-Persantine International Cooperative Study
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(i.e., cardiac-related death and nonfatal myocardial infarction)
for infarction-free survival.
Statistical analysis. Results are expressed as mean value 6
SD. Kaplan-Meier life-table estimates of infarction-free sur-
vival were used to summarize the follow-up experience in the
study patients and to clarify presentation. For survival analysis
only one event was considered for each patient. Patients who
died of noncardiac death were censored at the time of death.
Differences in survival curves were analyzed using the Mantel-
Haenszel test. The individual effect of certain variables on
infarction-free survival was evaluated with the use of the Cox
regression model (BMDP 2L, Department of Biomathematics,
University of California at Los Angeles, revised 1987). Accord-
ing to a stepwise selection process, variables were entered into,
or removed from, the regression equation on the basis of a
computed significance probability value (maximized partial
likelihood ratio).
Variables selected for examination were age; gender; pre-
vious myocardial infarction; ECG changes at baseline; rest left
ventricular function (evaluated through the wall motion score
index at rest); stress test results (positive/negative result, wall
motion score index at peak of drug infusion, rest–stress wall
motion score index variation, ST-T wave changes during test,
chest pain during test); and angiographic results defined both
according to the vessel involved (left anterior descending, left
circumflex or right coronary artery) and extent of stenosis
(75%, 90% or 100%). Continuous variables were compared by
means of the Student t test (two-tailed). Statistical analysis of
discrete variables was performed with the chi-square test. A p
value , 0.05 was considered statistically significant.
Results
Results of stress echocardiography. By inclusion criteria,
echocardiograms in all patients were considered interpretable
during testing and therefore suitable for analysis. In 31 pa-
tients, the test was submaximal for the occurrence of limiting
side effects; these test results (4% of all studies) were included
in the analysis. No major complications occurred during both
dipyridamole and dobutamine stress echocardiography.
Echocardiographic positivity was induced in 421 (56%) of
754 patients. Patients treated invasively had an higher inci-
dence of test positivity (69% vs. 49%, p , 0.001), left anterior
descending coronary artery involvement (60% vs. 46%, p ,
0.001) and 90% vessel stenosis (67% vs. 30%, p , 0.001) than
patients maintained with medical therapy (Table 1). In con-
trast, medically treated patients had a higher incidence of
recent myocardial infarction (54% vs. 36%, p , 0.001), right
(34% vs. 26%, p , 0.05) or left circumflex coronary artery
involvement (20% vs. 14%, p , 0.05) and 75% (26% vs. 16%,
p , 0.005) or 100% vessel stenosis (44% vs. 17%, p , 0.001)
than those treated invasively (Table 1). No difference between
medically and invasively treated patients was seen for both wall
motion score index at baseline (1.30 6 0.36 vs. 1.26 6 0.32, p 5
NS) and at peak drug infusion (1.48 6 0.39 vs. 1.46 6 0.37, p 5
NS) (Table 1).
Follow-up data. The mean duration of the follow-up was 37
months (range 2 to 140) and was ,1 year in 155 medically
treated patients (31%) and 96 invasively treated patients
(37%). During the follow-up period, 14 patients died of
cardiac-related and 15 of non–cardiac-related causes; further-
Table 1. Clinical, Angiographic, Baseline and Stress Echocardiographic Findings for Medically and
Invasively Treated Patients
Medically
Treated Patients
(n 5 494)
Invasively
Treated Patients
(n 5 260) p Value
Age (yr) 54 6 10 56 6 9 NS
Men 430 (87%) 215 (83%) NS
Recent (#15 days) MI 267 (54%) 95 (36%) , 0.001
Previous (.15 days) MI 125 (25%) 61 (23%) NS
Diseased vessel
LAD 230 (46%) 156 (60%) , 0.001
RCA 166 (34%) 68 (26%) , 0.05
LCx 98 (20%) 36 (14%) , 0.05
75% diameter stenosis 127 (26%) 42 (16%) , 0.005
90% diameter stenosis 148 (30%) 174 (67%) , 0.001
100% diameter stenosis 219 (44%) 44 (17%) , 0.001
WMSI at rest 1.30 6 0.36 1.26 6 0.32 NS
Abnormal ECG at rest 393 (79%) 179 (69%) , 0.005
Positive stress test result 240 (49%) 181 (69%) , 0.001
ECG changes during test 188 (38%) 168 (75%) , 0.001
Chest pain during test 130 (26%) 157 (60%) , 0.001
WMSI at peak of drug infusion 1.48 6 0.39 1.46 6 0.37 NS
Data presented are mean value 6 SD or number (%) of patients. ECG 5 electrocardiogram/electrocardiographic;
LAD 5 left anterior descending coronary artery; LCx 5 left circumflex coronary artery; MI 5 myocardial infarction;
RCA 5 right coronary artery; WMSI 5 wall motion score index.
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more, 40 patients had a nonfatal myocardial infarction. Of 54
hard cardiac events, 37 occurred in the subset of medically and
17 in the subset of invasively treated patients (7.5% vs. 6.5%,
p 5 NS). Two of the 54 events (cardiac death) were procedure
related.
After the first 3 months of follow-up, coronary revascular-
ization was performed in 48 (9.7%) (31 angioplasty, 17 oper-
ation) of medically treated patients and in 7 (2.7%) (all
operation) of the patients who underwent their first invasive
treatment soon after stress echocardiography (p , 0.001
between the two groups).
When the end point of hard cardiac events was considered,
univariate analysis identified two prognostic predictors for the
medically treated patients: a positive stress test result and
ischemic ECG changes during testing (Table 2). On multivar-
iate analysis, only a positive stress test result was found to be an
independent predictor of hard cardiac events (relative risk
2.92, 95% confidence interval 1.29 to 6.59, p 5 0.007).
When only medically treated patients were considered, the
4-year infarction-free survival rate was significantly higher for
those with a negative than for those with a positive result stress
test (93.9% vs. 87.3%, p 5 0.009) (Fig. 1). In contrast, when
only invasively treated patients were considered, a nonsignifi-
cant higher 4-year infarction-free survival rate was found for
those with a positive than for those with a negative stress test
result before coronary revascularization (97.1% vs. 92.7%, p 5
0.545) (Fig. 2). Of note, invasively treated patients had a
significantly higher 4-year infarction-free survival rate than did
medically treated patients when only the subgroup with a
positive stress test result was considered (p 5 0.012 vs. p 5
0.853 for a negative stress test result).
Discussion
Our results show that pharmacologic stress echocardiogra-
phy is effective in risk stratification of patients with single-
vessel disease, on the basis of the appearance of the induced
wall motion abnormalities. These data confirm and expand
previous experience with the strong prognostic power of
pharmacologic stress echocardiography in various patient
groups, ranging from those with chronic coronary artery dis-
ease (16–19) to patients evaluated after acute myocardial
infarction (15,20,21), before major vascular surgery (22,23)
and after coronary angioplasty (24).
Comparison with previous studies. In patients with single-
vessel disease, the prognostic importance of inducible ischemia
has been investigated with exercise ECG testing (4,5) and
exercise radionuclide angiography (6–8), with disappointing
results. Gibson et al. (9) found more valuable results with
stress thallium scintigraphy when “soft” end points (unstable
angina) were also considered. Parisi et al. (10) convincingly
showed that the presence of exercise-induced reversible thal-
lium perfusion defect was a valuable prognostic marker in
Table 2. Univariate Predictors of Prognosis in Medically Treated
Patients (events considered: cardiac death, nonfatal
myocardial infarction)
Chi-
Square p Value
Positive stress test result 7.49 0.0062
ECG changes during test 6.24 0.0125
90% diameter stenosis 2.39 0.1223
Chest pain during test 2.35 0.1254
Age 2.02 0.1548
Rest–stress WMSI variation 1.76 0.1847
75% diameter stenosis 0.89 0.3442
Previous MI 0.72 0.3972
100% diameter stenosis 0.44 0.5076
LAD 0.30 0.5844
WMSI at peak of drug infusion 0.19 0.6623
WMSI at rest 0.13 0.7209
RCA 0.11 0.7409
LCx 0.05 0.8207
Gender 0.01 0.9251
Abnormal ECG at baseline 0.00 0.9992
Abbreviations as in Table 1.
Figure 1. Cumulative survival rates free of hard cardiac events (death
and nonfatal infarction) in 494 medically treated patients with negative
(Neg) or positive (Pos) stress testing results.
Figure 2. Cumulative survival rates free of hard cardiac events (death
and nonfatal infarction) in 260 invasively treated patients with negative
(Neg) or positive (Pos) stress testing results before coronary revascu-
larization.
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patients with angiographically documented single- and double-
vessel disease and is superior to exercise electrocardiography
in this regard.
Our study differs from previous studies for three reasons: 1)
Stress echocardiography was used as the imaging technique; 2)
dipyridamole or dobutamine was used as an exercise-
independent stressor; and 3) the study cohort, prospectively
enrolled on a multicenter basis, totaled 754 patients, allowing
a statistically separate analysis for hard end points only.
Clinical implications. The results of our study confirm the
benign prognosis of single-vessel disease and identified as a
relatively higher risk subgroup those patients showing myocar-
dial ischemia elicitable by pharmacologic stress echocardiog-
raphy. Moreover, our data show that coronary revasculariza-
tion is effective in improving infarction-free survival in patients
with positive, but not in those with negative, stress echocardi-
ography. These findings have relevant implications for the
treatment of single-vessel disease: 1) Despite the fact that
preprocedural demonstration of myocardial ischemia is con-
sidered necessary in the American College of Cardiology/
American Heart Association Guidelines (25), to date there is
no evidence that coronary revascularization is effective in
reducing either mortality or subsequent myocardial infarction
in patients with single-vessel disease (26–28). 2) The practice
of performing coronary revascularization on the basis of
coronary anatomic findings only, without preprocedural eval-
uation of the patient by noninvasive stress testing, is a frequent
and particularly disturbing therapeutic option, overloading the
health care system (29).
At present, careful stratification of patient risk by pharma-
cologic stress echocardiography seems to represent an effective
strategy for selection of patients in whom coronary revascular-
ization can have maximal beneficial effects in terms of prog-
nosis, with the potential of improved cost-effectiveness for
invasive procedures.
Limitations of the study. Our study was observational, not
randomized, and the decision for medical treatment over
coronary revascularization was made by the physician on the
basis of clinical, anatomic and stress echocardiographic find-
ings. It is possible that the intentional dropout process created
a bias by exclusion of patients who would be expected to have
a worse prognosis.
The angiographic evaluation was crude, with visual estima-
tion of stenosis. No quantitative assessment was performed,
and the analysis did not include assessment of plaque morphol-
ogy, collateral circulation, site of stenosis or coronary domi-
nance pattern. Nevertheless, simple visual assessment of cor-
onary anatomy defines a readily identifiable angiographic
subset.
We pooled the results obtained with dipyridamole and
dobutamine stress, although dipyridamole and dobutamine
induce ischemia by different physiologic mechanisms (30).
Nevertheless, the two tests have virtually identical diagnostic
accuracy, with the slightly higher sensitivity of dobutamine for
single-vessel disease balanced by the higher specificity of
dipyridamole, as has been made clear by the experience
obtained from directly comparing the two tests in .500
patients undergoing coronary angiography (31). The guidelines
of the American College of Cardiology/American Heart Asso-
ciation explicitely state that “stress echocardiography by either
exercise or pharmacological challenge (using vasodilators or
dobutamine) is both sensitive and specific for detecting induc-
ible myocardial ischemia in patients with intermediate to high
pretest probability of coronary artery disease” (32). Moreover,
it has been demonstrated that dobutamine and dipyridamole
stress echocardiography has a virtually identical capability of
prognostic stratification (33,34).
In our study there was no centralized reading of stress
echocardiogram. Each echocardiogram (either at baseline or
during stress) was interpreted at the peripheral center, and this
reading was directly entered into the data bank. Results might
have been affected by interinstitutional variability in readings
of stress echocardiograms (35). However, this system allowed
substantial sparing of human and technologic resources.
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